Pharmathen
Pharmathen S.A., a leading pharmaceutical company headquartered in Greece (GR), has established itself as a key player in the global healthcare industry since its founding in 1975. With a strong presence in Europe, the Middle East, and Africa, Pharmathen focuses on the development, manufacturing, and marketing of innovative generic and specialty pharmaceuticals. The company is renowned for its advanced drug delivery systems and high-quality formulations, which cater to a diverse range of therapeutic areas. Notable achievements include significant investments in research and development, positioning Pharmathen as a trusted partner for both healthcare professionals and patients. With a commitment to excellence and a robust portfolio of products, Pharmathen continues to enhance its market position and contribute to the advancement of global health.
DitchCarbon Score
How does Pharmathen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmathen's score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmathen's reported carbon emissions
In 2024, Pharmathen reported total carbon emissions of approximately 166,000,000 kg CO2e, comprising 6,390,000 kg CO2e from Scope 1, 8,849,000 kg CO2e from Scope 2, and a significant 155,577,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions include major contributions from purchased goods and services (about 130,164,000 kg CO2e) and waste generated in operations (approximately 9,805,000 kg CO2e). Pharmathen has set ambitious climate commitments, targeting a 45% reduction in greenhouse gas (GHG) emissions by 2030, with a focus on increasing the share of renewable energy and enhancing energy efficiency across its operations. This target applies to both Scope 1 and Scope 2 emissions. In 2023, the company achieved a 9% reduction in total GHG emissions compared to the base year of 2022, attributed to a greater reliance on renewable energy sources. Additionally, Pharmathen has formalised a pledge to achieve net-zero emissions by 2050, encompassing all scopes of emissions. This long-term commitment reflects the company's strategic approach to sustainability and carbon neutrality. Pharmathen's emissions data is not cascaded from any parent organisation, indicating that the figures are independently reported. The company continues to prioritise sustainability as a core aspect of its operational strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 13,736,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,125,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmathen is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
